Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports

Leukemia & Lymphoma
C StruppR Haas

Abstract

The histological morphology of AILD-type T-cell lymphoma shows proliferation of small, arborizing high endothelial venules. Patients typically have generalized lymphadenopathy, fever, weight loss, skin rash, polyclonal hypergammaglobulinemia and autoimmune phenomena, and are susceptible to infections. The clinical course is usually aggressive. About 30% of patients have an initial remission on steroids alone, but most require some form of cytotoxic chemotherapy. Median survival ranges from 15 to 24 months, and it appears that the disease cannot be cured. We have used anti-angiogenetic therapy with thalidomide in two AILD patients and observed remarkable responses.

References

Dec 1, 1981·Cancer·P K SchauerB D Clarkson
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·R J D'AmatoJ Folkman
Feb 28, 2001·Leukemia Research·J LindahlE Hellström-Lindberg

❮ Previous
Next ❯

Citations

Mar 8, 2006·Nature Clinical Practice. Oncology·Stephanie HaleneNancy Berliner
Oct 15, 2005·Current Opinion in Oncology·Ad Koster, John M M Raemaekers
May 29, 2010·Journal of Oncology·Michael MedingerAlexandar Tzankov
Oct 12, 2011·Acta Haematologica·Tsutomu KobayashiMasafumi Taniwaki
Oct 2, 2012·The Journal of Clinical Investigation·Stefano A Pileri, Pier Paolo Piccaluga
Feb 1, 2014·International Journal of Hematology·Pier Paolo PiccalugaStefano A Pileri
Jan 29, 2009·Acta Oncologica·Fadi BraitehPeter McLaughlin
Jun 25, 2010·Leukemia & Lymphoma·Jennifer E Amengual, Bruce G Raphael
Apr 25, 2007·Leukemia & Lymphoma·Barbara Pro, Peter McLaughlin
Aug 8, 2008·Critical Reviews in Oncology/hematology·Emilio IannittoHans H Kreipe
Jun 26, 2007·La Presse médicale·Florence Lachenal
Feb 14, 2004·European Journal of Haematology·C StruppR Haas
Mar 24, 2007·European Journal of Haematology·José RodríguezUNKNOWN Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea
Jun 9, 2007·British Journal of Haematology·Yuanping ZhouMing-Qing Du
Apr 13, 2011·British Journal of Haematology·Claire E DeardenUNKNOWN British Committee for Standards in Haematology
Dec 8, 2009·British Journal of Haematology·Laurence de LevalPhilippe Gaulard
Jun 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaji KumarS Vincent Rajkumar
Dec 1, 2007·Hematological Oncology·Delvys Rodriguez-AbreuEmanuele Zucca
Mar 23, 2011·Expert Review of Anticancer Therapy·Rebecca A Howman, H Miles Prince
Sep 24, 2011·Expert Review of Hematology·Fernando RoncolatoPier Paolo Piccaluga
Dec 14, 2004·Stem Cells and Development·Domenico RibattiAngelo Vacca
Jun 5, 2003·British Journal of Haematology·Ahmet DoganChara Kyriakou
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charalampia KyriakouUNKNOWN Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.